Business Wire

ACOLIN-FUND-SERVICES-AG

Share
b-public AG: ACOLIN strengthens strategic growth through management buy-out from Sovereign Capital Partners (news with additional features)

ACOLIN Fund Services AG, a leading Switzerland-based provider of regulatory and cross-border fund distribution services, is delighted to announce a significant investment in its business following the management buy-out by Sovereign Capital Partners, the UK private equity Buy & Build specialist. Sovereign has partnered with ACOLIN's management team to further develop its client base and service offering through a strategy of organic and acquisitive growth.

With Sovereign's support, ACOLIN will work further towards its goal of becoming a leading one-stop-shop service provider along the entire investment funds distribution value chain. Its growth plans include acquisition of specialized firms to enhance and widen the scope of its services. The company's ambitious geographical expansion plans target additional European countries as well as Asia, Middle East and the Americas.

Sovereign is backing the management team of ACOLIN by appointing two representatives Alex Hay, Partner, and Nate Janks, Investment Manager, to the Board of Directors. Mike Covell, previously a Managing Director at Goldman Sachs and Chairman of Tilney, will further enhance the Board of Directors as Non-Executive Chairman.

Daniel Haefele, founder, Executive Vice-Chairman and CEO of ACOLIN commented: "Our management team is thrilled about the new partnership with Sovereign. I am personally very satisfied to have found the right partner who shares our conviction in the success of ACOLIN's business model. With Sovereign's investment and expertise, we look forward to further enhancing our offering, adding new services and taking even better care of our clients' needs."

Established in 2006 in Zurich, ACOLIN is a success story in European financial services, catering to the specific needs of asset managers in cross-border fund distribution. ACOLIN helps its clients to access new markets, meet regulatory obligations and grow Assets under Management across multiple jurisdictions. The business represents investment funds across various markets, ensuring that all regulatory obligations are rigorously fulfilled, and that fund data and documents are available to investors, intermediaries and to the relevant authorities. The business currently provides services to over 600 asset managers - ca.14% of those active in Europe - representing some 1800 investment funds across 30 countries.

In addition, ACOLIN's proprietary distribution network facilitates clients' quick access to a wide array of fund distribution channels across Europe, overseeing data and commission management for over €20bn of Assets under Management together with ongoing monitoring and due diligence of distribution partners.

Daniel Haefele commented: "Since I established the business fourteen years ago, the cross-border fund distribution regulatory landscape has become increasingly complex and it continues to evolve. We recognize huge potential in this area combined with increasing demand for more comprehensive, client-focused and customized services, and the business is uniquely well positioned to take advantage of this growth opportunity."

Alex Hay, Partner, Sovereign added: "We are delighted to be backing Daniel and his first-class management team as the business looks to its next stage of growth. We believe that through strategic Buy & Build, ACOLIN is well positioned to further develop its offering and geographic reach in this fragmented market."

The change in the shareholding will not impact the employment status of ACOLIN's current staff.

- ENDS -

About ACOLIN Fund Services AG (ACOLIN)

ACOLIN is the only globally active provider of cross-border fund distribution services that operates independently of banks. The comprehensive range of services offered by ACOLIN enables internationally active asset managers and fund companies to gain swift and straightforward access to the most important global financial markets in the EU, Switzerland, Asia and Latin America.

ACOLIN ensures the smooth registration of funds, performs legal representation duties and manages compliance with all regulatory requirements. Headquartered in Zurich, ACOLIN has subsidiaries and branches in Belgrade, Dublin, Frankfurt, Geneva, Constance, London, Milan and Madrid.

www.acolin.com

About Sovereign Capital Partners

Established in 2001, Sovereign Capital Partners LLP is a UK-based private equity firm that invests in high quality service-based businesses, partnering with management teams to help them grow through organic and acquisitive means, extending the client service offering and geographic coverage to achieve accelerated growth. Sovereign Capital Partners LLP is regulated and authorised by the FCA.

www.sovereigncapital.co.uk


Additional features:Picture: http://newsfeed2.eqs.com/bpublic/1059387.html
Subtitle: New shareholders of ACOLIN in a teleconference confirming the management buy-out of the company

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

AwardFares Launches Intelligent New Alert System for Award Flight Availability5.8.2025 08:00:00 CEST | Press release

AwardFares, the leading search platform for award flights, today launched a major upgrade to its alert system, giving users smarter tools to discover and book award availability faster. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804412041/en/ AwardFares' Timeline view provides a clear, color-coded visualization of daily award seat availability across different cabin classes, helping users easily spot trends and opportunities for flights. The new system includes two powerful features: Flex Alerts and Live Alerts. Together, they provide both flexibility and precision, helping travelers maximize their points and miles like never before. Flex Alerts are designed for the flexible traveler. Instead of requiring an exact route and date, users can set broad criteria such as "any airport in the US to Europe for an entire month.” AwardFares' AI-powered system intelligently identifies matching availability, focusing not just on

Venture Global Calcasieu Pass Receives Uprate Approval from U.S. Department of Energy5.8.2025 02:02:00 CEST | Press release

Today, Venture Global, Inc. (NYSE: VG) received approval from the U.S. Department of Energy (DOE) for an uprate amendment to its Calcasieu Pass LNG project. The uprate approval increases Calcasieu Pass’ permitted peak liquefaction capacity from 12.0 million tonnes per annum (MTPA) to 12.4 MTPA. “Venture Global thanks its regulators, including DOE, for their efforts in prioritizing and streamlining approvals for critical energy infrastructure projects. These multibillion dollar investments will be key as the United States strengthens global energy security and increases energy trade with our partners around the world,” said Venture Global CEO Mike Sabel. Calcasieu Pass, Venture Global’s first project, reached first LNG production in 2022 and began commercial operations in April 2025. The company’s second facility, Plaquemines LNG, began LNG production in December 2024. Venture Global’s third project, CP2, received DOE export authorization and FERC approval in March 2025 and May 2025, re

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain4.8.2025 22:01:00 CEST | Press release

– Treatment with the selective NaV1.8 pain signal inhibitor VX-993 after bunionectomy surgery did not meet the primary endpoint –– Treatment with VX-993 was generally safe and well tolerated, with safety profile similar to placebo arm – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, randomized, double-blind, placebo-controlled dose-ranging study evaluating the safety and efficacy of its investigational selective NaV1.8 pain signal inhibitor, VX-993, in treating acute pain after bunionectomy surgery. Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated. Most adverse events (AEs) were mild to moderate, and there were no serious adverse events (SAEs) related to VX-993. Based on these results, Vertex will not progress

TOURISE Announces Cross-Sector Advisory Board to Champion Bold New Platform Rewriting the Rules of Tourism4.8.2025 20:53:00 CEST | Press release

Leaders from World Travel & Tourism Council (WTTC), Global Sustainable Tourism Council, Amadeus, TikTok, Six Senses, Cirque du Soleil, Turismede Barcelona, Liberty International, Wagonlit Travel, Once Billion Happy, the Saudi Tourism Authority (STA), and the Riyadh School of Tourism and Hospitality at the helm of TOURISE Advisory Board Formation of the Advisory Board reinforces TOURISE’s dedication to driving cross-sector global collaboration Advisory Board shape TOURISE summit agenda, ensuring high-impact global issues such as equity, geographical representation and sectoral diversity are in spotlight TOURISE, the bold new global tourism platform, has announced the members of its cross-sector Advisory Board, a powerhouse of industry titans guiding TOURISE’s strategic direction and shaping the agenda of the inaugural global summit taking place in Riyadh from 11-13 November, 2025. TOURISE is where cross-sector convergence begins, a platform where leaders and visionaries debate, collabor

Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Trial, Expanding its Coronary Clinical Program Across the U.S. and Europe4.8.2025 20:38:00 CEST | Press release

Concept Medical Inc., a global pioneer in drug-delivery technologies, announced the enrollment of the first patient in the MAGICAL-SV (MAGIcTouch™ Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels) trial, a U.S. Investigational Device Exemption (IDE) study evaluating its MagicTouch™ sirolimus-coated balloon (SCB) for the treatment of small coronary vessels. This first U.S. enrollment follows the FDA’s IDE approval of MagicTouch SCB, marking a major milestone in Concept Medical’s mission to revolutionize coronary artery disease (CAD) treatment and expand its clinical program into the US and Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250804524652/en/ Concept Medical Announces First Patient Enrollment in MAGICAL-SV IDE Study Dr. Samin Sharma enrolled the first patient at New York’s Mount Sinai Hospital, Director of Interventional Cardiology, marking a crucial step in advancing treatm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye